Penile Cancer References

REFERENCES

Van Poppel H, Watkin NA, Osanto S, et al; ESMO Guidelines Working Group. Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24(Suppl 6):vi115-124. doi: 10.1093/annonc/mdt286. PMID: 23975666
Hakenberg OW, Comperat E, Minhas S, et al. Guidelines on penile cancer. European Association of Urology (EAU). http://uroweb.org/wp-content/uploads/EAU-Guidelines-Penile-Cancer-2015-v2.pdf. Apr 2015.
National Cancer Institute: PDQ® Penile cancer treatment. Bethesda, MD: National Cancer Institute. http://www.cancer.gov/types/penile/hp/penile-treatment-pdq. 5 Feb 2015.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: penile cancer version 3.2015. NCCN. http://www.nccn.org/professionals/physician_gls/pdf/penile.pdf. 4 Mar 2015.
Pettaway CA. Carcinoma of the penis: clinical presentation and diagnosis. UpToDate. http://www.uptodate.com/contents/carcinoma-of-the-penis-clinical-presentation-and-diagnosis. 13 May 2014.
Pettaway CA. Carcinoma of the penis: epidemiology, risk factors, staging, and prognosis. UpToDate. http://www.uptodate.com/contents/carcinoma-of-the-penis-epidemiology-risk-factors-staging-and-prognosis?source=see_link. 15 Jan 2015.
Pettaway CA. Carcinoma of the penis: surgical and medical treatment. UpToDate. http://www.uptodate.com/contents/carcinoma-of-the-penis-surgical-and-medical-treatment. 27 Apr 2015.
Hakenberg OW, Comperat E, Minhas S, Necchi A, Protzel C, Watkin N. EAU guidelines on penile cancer. European Association of Urology (EAU). http://uroweb.org/wp-content/uploads/EAU-Guidelines-Penile-Cancer-2016.pdf. Apr 2016. Accessed 13 Oct 2016.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: penile cancer version 2.2016. NCCN website. https://www.nccn.org/professionals/physician_gls/pdf/penile.pdf. 27 Jun 2016.

Denosumab: A critical aspect of metastatic prostate cancer treatment

Prof. Bertrand Tombal, Assoc Prof. Edmund Chiong, 18 May 2022

Men with metastatic prostate cancer (mPC) have an elevated risk of skeletal complications either due to bone metastases (skeletal-related events [SREs]), or from osteoporosis induced by androgen deprivation therapy (ADT). Two key opinion leaders recently shared their perspectives on bone complications in mPC as well as the use of bone-targeted agents (BTAs) such as denosumab (Xgeva) to reduce the risk of bone complications.

Professor Bertrand Tombal

Professor of Urology

Cliniques universitaires Saint-Luc & Université catholique de Louvain

Brussels, Belgium

Associate Professor Edmund Chiong

Head, Department of Urology

National University Hospital, Singapore

Product Highlight - ZAVICEFTA

12 Sep 2023

Ceftazidime 2 g, avibactam 0.5 g powder for concentrate for solution for infusion

Antioxidant and micronutrient supplementation on the sperm parameters of male patients with idiopathic infertility: An updated literature review

09 Jun 2020

Infertility is a problem faced by 5-10 percent of couples, with male factor accounting for up to 47 percent of cases. [Int J Androl 1987;7(Suppl):1]. There are many causes for male infertility but up to 15 percent of cases are idiopathic in nature. These cases may be related to unregulated excessive oxidative stress, which may impair spermatogenesis; hence, arousing research into the role of antioxidant supplementation in improving the sperm parameters.